Page 265 - 2021_06-Haematologica-web

Case Reports
Cristoforo Pomara,1 Francesco Sessa,2 Marcello Ciaccio,3,4 Francesco Dieli,5 Massimiliano Esposito,1 Sebastiano Fabio Garozzo,6 Antonino Giarratano,7,8 Daniele Prati,9
Francesca Rappa,10 Monica Salerno,1 Claudio Tripodo,11 Paolo Zamboni12 and Pier Mannuccio Mannucci9
1Department of Medical, Surgical and Advanced Technologies G.F. Ingrassia, University of Catania, Catania; 2Department of Clinical and Experimental Medicine, University of Foggia, Foggia; 3Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo; 4Department of Laboratory Medicine, AOUP “P. Giaccone”, Palermo;
5Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, Palermo; 6Clinical Pathology Unit, Garibaldi Centro Hospital, ARNAS Garibaldi, Catania; 7Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo; 8Department of Anesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo; 9Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Blood Transfusion Center, Milan; 10Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo; 11Tumor Immunology Unit, Department of Health Sciences, University School of Medicine of Palermo, Palermo and 12Vascular Diseases Center, Mini-invasive Venous Surgery Unit, University of Ferrara, Ferrara, Italy
Correspondence: PIER MANNUCCIO MANNUCCI - piermannuccio.mannucci@policlinico.mi.it doi:10.3324/haematol.2021.279075
Received: April 23, 2021.
Accepted: May 13, 2021.
Pre-published: May 20, 2021.
Disclosures: no conflicts of interest to disclose.
Contributions: all authors equally contributed to the preparation of the case report.
Acknowledgments: we thank the staff of the public prosecutor office of Catania and Gela and the Department of Health of the Sicily Region for help and assistance during the post-mortem examination.
References
1. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov- 19 vaccination. N Engl J Med. 2021;384(22):2092-2101.
2. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124-2130.
3. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202-2211.
4. See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccina- tion, March 2 to April 21, 2021. JAMA. 2021;325(24):2448-2456.
5. GreseleP,MariettaM,AgenoW,etal.Managementofcerebraland splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). Blood Transfus. 2021 Apr 15. [Epub ahead of print]
6. Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL. Validation of the high-dose heparin confirmatory step for the diag- nosis of heparin-induced thrombocytopenia. Blood. 2010; 116(10):1761-1766.
haematologica | 2021; 106(8)
2293